ES2057016T3 - Compuestos de acido 3-pirrolidiniltio-1-azabiciclo (3.2.0) hept-2-eno-2-carboxilico. - Google Patents

Compuestos de acido 3-pirrolidiniltio-1-azabiciclo (3.2.0) hept-2-eno-2-carboxilico.

Info

Publication number
ES2057016T3
ES2057016T3 ES89108896T ES89108896T ES2057016T3 ES 2057016 T3 ES2057016 T3 ES 2057016T3 ES 89108896 T ES89108896 T ES 89108896T ES 89108896 T ES89108896 T ES 89108896T ES 2057016 T3 ES2057016 T3 ES 2057016T3
Authority
ES
Spain
Prior art keywords
alkyl
pirrolidinyltio
azabiciclo
carboxilico
eno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89108896T
Other languages
English (en)
Inventor
Masayoshi Murata
Hideo Tsutsumi
Keiji Matsuda
Kohji Hattori
Takashi Nakajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888812160A external-priority patent/GB8812160D0/en
Priority claimed from GB898906576A external-priority patent/GB8906576D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2057016T3 publication Critical patent/ES2057016T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN COMPONENTE DE LA FORMULA (I): EN EL CUAL R1 ES CARBOXI O CARBOXI PROTEGIDO, R2 ES HIDROXIALQUILO INFERIOR O EL MISMO PROTEGIDO R3 ES HIDROGENO O ALQUILO, INFERIOR, R4 ES UN GRUPO ETEROCICLICO INSATURADO QUE PUEDE SER SUSTITUIDO POR SUSTITUYENTES ADECUADOS, R5 ES HIDROGENO O UN GRUPO HIMINOPRECTOR O UN ALCANIMIDOIL INFERIOR, Y A ES UN ALQUILENO INFERIOR, O SALES FARMACEUTICAMENTE ACEPTABLES DE ELLO, PROCESO PARA SU PREPARACION Y COIMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN COMO INGREDIENTE ACTIVO MEZCLADO CON UN PORTADOR ACEPTABLE FARMACEUTICAMENTE O UN EXCIPIENTE.
ES89108896T 1988-05-23 1989-05-18 Compuestos de acido 3-pirrolidiniltio-1-azabiciclo (3.2.0) hept-2-eno-2-carboxilico. Expired - Lifetime ES2057016T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888812160A GB8812160D0 (en) 1988-05-23 1988-05-23 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds
GB898906576A GB8906576D0 (en) 1989-03-22 1989-03-22 3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid compounds

Publications (1)

Publication Number Publication Date
ES2057016T3 true ES2057016T3 (es) 1994-10-16

Family

ID=26293918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89108896T Expired - Lifetime ES2057016T3 (es) 1988-05-23 1989-05-18 Compuestos de acido 3-pirrolidiniltio-1-azabiciclo (3.2.0) hept-2-eno-2-carboxilico.

Country Status (7)

Country Link
US (1) US4963544A (es)
EP (1) EP0343499B1 (es)
JP (1) JP2792103B2 (es)
KR (1) KR900018099A (es)
AT (1) ATE109149T1 (es)
DE (1) DE68917023T2 (es)
ES (1) ES2057016T3 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923844D0 (en) * 1989-10-23 1989-12-13 Fujisawa Pharmaceutical Co Carbapenem compounds
US5227376A (en) * 1990-02-14 1993-07-13 Sumitomo Pharmaceuticals Co., Ltd. β-lactam compounds and their production
US5554606A (en) * 1990-03-12 1996-09-10 Zeneca Limited Antibiotic compounds
GB9107342D0 (en) * 1991-04-08 1991-05-22 Ici Plc Antibiotic compounds
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
GB9304156D0 (en) * 1992-03-26 1993-04-21 Zeneca Ltd Antibiotic compounds
EP0636133A1 (en) * 1992-04-13 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents
CA2099818A1 (en) * 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
CA2099811A1 (en) * 1992-07-21 1994-01-22 Frederic H. Jung Antibiotic compounds
GB9320816D0 (en) * 1993-10-08 1993-12-01 Fujisawa Pharmaceutical Co Novel compounds
DE69523574T2 (de) * 1994-02-25 2002-05-29 Banyu Pharma Co Ltd Carbapenem-derivate
JP3848693B2 (ja) * 1994-07-06 2006-11-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規カルバペネム誘導体
TW445265B (en) * 1996-11-25 2001-07-11 Meiji Seika Kaisha Carbapenem derivatives and antimicrobial agents
CA2584507C (en) 2004-10-20 2016-04-26 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US7932381B2 (en) 2005-02-15 2011-04-26 Shionogi & Co., Ltd. Process for producing carbapenem derivative and intermediate crystal therefor
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
AU2009262252B2 (en) 2008-06-26 2013-05-02 Resverlogix Corp. Methods of preparing quinazolinone derivatives
ES2463097T3 (es) 2009-01-08 2014-05-27 Resverlogix Corp. Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR102215167B1 (ko) 2009-04-22 2021-02-16 리스버로직스 코퍼레이션 신규한 소염제
CA2848012A1 (en) 2011-09-09 2013-03-14 Cubist Pharmaceuticals, Inc. Methods for treating intrapulmonary infections
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
MX2020004205A (es) 2013-03-15 2021-11-16 Merck Sharp & Dohme Llc Composiciones antibioticas de ceftolozano.
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552873A (en) * 1981-08-19 1985-11-12 Sankyo Company Limited Carbapenem compounds, and compositions containing them
JPS5916892A (ja) * 1982-07-19 1984-01-28 Sankyo Co Ltd カルバペネム−３−カルボン酸誘導体およびその製法
KR900006449B1 (ko) * 1982-08-24 1990-08-31 상꾜 가부시끼가이샤 아제티디논 화합물의 제조방법
US4746736A (en) * 1982-09-28 1988-05-24 Bristol-Myers Company Carbapenem antibiotics
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
JPS60202886A (ja) * 1984-03-27 1985-10-14 Sankyo Co Ltd １―置換カルバペネム―３―カルボン酸誘導体
CA1281720C (en) * 1984-11-08 1991-03-19 Makoto Sunagawa Carbapenem compounds and production thereof
DE3780344T2 (de) * 1986-03-27 1993-01-28 Sumitomo Pharma Beta-lactam-verbindungen und deren herstellung.
EP0272455B1 (en) * 1986-11-24 1993-02-10 Fujisawa Pharmaceutical Co., Ltd. 3-Pyrrolidinylthio-1-azabicyclo [3.2.0] hept-2-ene-2-carboxylic acid compounds
KR880006244A (ko) * 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법

Also Published As

Publication number Publication date
JPH0215080A (ja) 1990-01-18
EP0343499B1 (en) 1994-07-27
ATE109149T1 (de) 1994-08-15
US4963544A (en) 1990-10-16
EP0343499A1 (en) 1989-11-29
KR900018099A (ko) 1990-12-20
DE68917023T2 (de) 1994-12-08
JP2792103B2 (ja) 1998-08-27
DE68917023D1 (de) 1994-09-01

Similar Documents

Publication Publication Date Title
ES2057016T3 (es) Compuestos de acido 3-pirrolidiniltio-1-azabiciclo (3.2.0) hept-2-eno-2-carboxilico.
DE68916071T2 (de) 3-Pyrrolidinylthio-1-azabicyclo (3.2.0)hept-2-en-2-carbonsäure-Verbindungen.
DE68925223D1 (de) 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-en-2-carbonsäure-Verbindungen
NO903438D0 (no) Fremgangsmaate for fremstilling av tiazolderivater.
NO178697C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrazolopyridin-forbindelser
LU91362I2 (fr) Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)
DK96786A (da) Aminosyrederivater
IL103826A0 (en) Thiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
FI895139A0 (fi) Pyrrolidinderivat.
ES2061579T3 (es) Compuestos cefem y procedimientos para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 343499

Country of ref document: ES